Original research

Biomedical Research and Therapy

, 3:46

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Adipose derived stem cell transplantation is better than bone marrow mesenchymal stem cell transplantation in treating hindlimb ischemia in mice

  • Ngoc Bich VuAffiliated withLaboratory of Stem Cell Research and Application, University of Sciences, Vietnam National University
  • , Lan Thi PhiAffiliated withLaboratory of Stem Cell Research and Application, University of Sciences, Vietnam National University
  • , Thuy Thi-Thanh DaoAffiliated withLaboratory of Stem Cell Research and Application, University of Sciences, Vietnam National University
  • , Ha Thi-Ngan LeAffiliated withLaboratory of Stem Cell Research and Application, University of Sciences, Vietnam National University
  • , Van Thanh TaAffiliated withHanoi Medical University
  • , Phuc Van PhamAffiliated withLaboratory of Stem Cell Research and Application, University of Sciences, Vietnam National UniversityFalcuty of Biology and Biotechnology, University of Sciences, Vietnam National University Email author 

Abstract

Introduction:

Bone marrow derived MSCs (BM-MSCs) and adipose derived MSCs (AD-MSCs) are among the types of stem cells most commonly studied. Our study aims to compare the therapeutic efficacy of allograft AD-MSCs versus BM-MSCs in a mouse model of hindlimb ischemia.

Methods:

AD-MSCs were isolated from belly fat and BM-MSCs were isolated from femur bone marrow. They were used to treat mice with acute hindlimb ischemia. Treatment efficacy was compared among 4 groups: injected with BM-MSCs, injected with AD-MSCs, non-treated and injected with phosphate buffered saline. Mice in the groups were evaluated for the following: necrosis grade of leg, leg edema, blood flow, muscle cell restructure and new blood vessel formation.

Results:

Results showed that AD-MSC transplantation significantly recovered acute limb ischemia, with 76.5% of mice fully recovered, while the ratio was only 48.5% in BM-MSC transplanted group, and 0% in the non-treated and PBS groups. Evaluation of leg edema, blood flow, muscle cell restructure and new blood vessel formation also supported the observation that AD-MSC transplantation was superior over BM-MSC transplantation.

Conclusion:

Therefore, AD-MSCs may serve as the more suitable MSC for hindlimb ischemia treatment and angiogenesis therapy.

Keywords:

Mesenchymal stem cell adipose derived stem cell bone marrow derived stem cell allograft hindlimb ischemia